$187.2 M

MIRN Mkt cap, 15-Aug-2018

$608 K

Mirna Therapeutics Revenue Q2, 2018
Mirna Therapeutics Net income (Q2, 2018)-25.8 M
Mirna Therapeutics EBIT (Q2, 2018)-27 M
Mirna Therapeutics Cash, 30-Jun-201826.6 M

Mirna Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

2.4 m

R&D expense

18.9 m13.9 m30.3 m

General and administrative expense

6.1 m8.1 m12.9 m

Operating expense total

25 m22 m43.3 m

EBIT

(40.8 m)

EBIT margin, %

(1670%)

Interest expense

57 k

Interest income

44 k350 k

Net Income

(25 m)(26.3 m)(40.4 m)

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2018Q2, 2018

Revenue

354 k608 k

R&D expense

4.5 m3.7 m3.4 m8.4 m19.2 m

General and administrative expense

1.6 m2.1 m2 m1.9 m3.6 m8.4 m

Operating expense total

6.2 m6.7 m5.7 m5.3 m12 m27.6 m

EBIT

(11.6 m)(27 m)

EBIT margin, %

(3287%)(4439%)

Interest expense

8 k14 k26 k

Interest income

82 k93 k97 k

Net Income

(6.2 m)(6.6 m)(5.6 m)(5.4 m)(11.2 m)(25.8 m)

Mirna Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

89.7 m16.4 m58.4 m

Inventories

793 k882 k

Current Assets

90.5 m61.4 m88.6 m

PP&E

375 k354 k9.8 m

Total Assets

90.9 m64.2 m99.7 m

Accounts Payable

3.7 m361 k2.7 m

Current Liabilities

5.9 m2.8 m9 m

Non-Current Liabilities

5.6 m

Total Liabilities

3.8 m

Additional Paid-in Capital

161.5 m163.1 m156.7 m

Retained Earnings

(76.5 m)(102.8 m)(71.7 m)

Total Equity

85 m60.4 m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ3, 2015Q1, 2018Q2, 2018

Cash

35.7 m27.2 m26.6 m

Current Assets

36.1 m127.9 m145.3 m

PP&E

266 k13.7 m14.6 m

Total Assets

38.1 m142.7 m161.1 m

Accounts Payable

2.2 m1.3 m1.1 m

Current Liabilities

5 m7 m8.2 m

Non-Current Liabilities

6.9 m8.3 m

Additional Paid-in Capital

211.4 m241.8 m

Retained Earnings

(67.7 m)(82.5 m)(97.1 m)

Total Equity

128.8 m144.6 m

Financial Leverage

1.1 x1.1 x

Mirna Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(25 m)(26.3 m)(40.4 m)

Depreciation and Amortization

54 k159 k2.3 m

Inventories

793 k107 k

Accounts Payable

3.7 m(3.3 m)4.1 m

Cash From Operating Activities

(21.1 m)(24.8 m)

Purchases of PP&E

(251 k)(1.7 m)(2.6 m)

Cash From Investing Activities

(251 k)(48.5 m)

Cash From Financing Activities

67 k16 k

Interest Paid

35 k

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(6.2 m)(6.6 m)(5.6 m)(5.4 m)(11.2 m)(25.8 m)

Depreciation and Amortization

681 k1.2 m

Accounts Payable

2.2 m1.2 m1.5 m1.2 m371 k47 k(3 m)(1.3 m)

Cash From Operating Activities

(13 m)(23.8 m)

Purchases of PP&E

(1.9 m)(2.9 m)

Cash From Investing Activities

(71.9 m)(90.4 m)

Cash From Financing Activities

53.6 m82.4 m

Interest Paid

14 k25 k

Mirna Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Mirna Therapeutics Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42
Report incorrect company information